Cancer, in its myriad forms, continues to be a significant global health challenge, impacting millions of individuals worldwide. Amidst this, multidisciplinary treatment approaches are crucial in the management and control of the disease, accommodating the wide array of oncological diagnoses and patient needs. Over the years, the philosophy of cancer treatment has witnessed a fundamental shift, moving from a 'maximum tolerable' approach to a 'minimum effective' strategy. This evolution, firstly in breast cancer management and then in other oncological diagnosis, seeks to balance optimal therapeutic outcomes with the minimal negative impact on patients' quality of life, marking a significant advance in patient-centric care.
Crucial to these multidisciplinary strategies is not only the goal of clinical remission or control of the disease but also the holistic well-being of patients. Recognizing the essentiality of their emotional, psychological, and social health is paramount in formulating an effective treatment plan.
In the contemporary landscape of oncology, we find ourselves armed with a wider range of innovative technologies and treatment strategies than ever before. These advancements are not merely limited to surgical interventions but span the spectrum of systemic and locoregional treatments, empowering us with more tools to customize treatment strategies and design individualized care plans. Non operative management with surgical de-escalation or even surgical omission in several solid tumors and Chemotherapy-Sparing Regimen are only two examples of this physolophy, aiming at oncological disease chronicity, reduced side effect maintaining surgical safety.
In this Research Topic, our aim is to illuminate the latest developments in oncology from this perspective. We will focus on how evolving strategies in multidisciplinary treatment align with the broader objective of enhancing patients' quality of life. We intend to highlight the intricate relationships between different forms of systemic and locoregional treatments and their implications on patients' well-being, as well as the critical role of patient-reported outcomes (PROMs) in this context. Under this perspective, we strongly believe that no specific organ-based special issue should be held reducing the disease particularism, but a broaden oncological population cohort could enhance the scientific evidence in biologically different pathologies.
Accordingly, we invite submissions in the form of case reports, case series, technical notes, review articles, and original research papers that contribute to this conversation. We particularly encourage studies that delve into oncological outcomes and their integration with the broader framework of patient health and quality of life.
Thank you for contributing to this essential dialogue in oncology. Through our collective efforts, we can indeed bring about a positive difference in the lives of those affected by this formidable disease.
Please note: manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent clinical or patient cohort, or biological validation in vitro or in vivo, which are not based on public databases) are not suitable for publication in this journal.
Cancer, in its myriad forms, continues to be a significant global health challenge, impacting millions of individuals worldwide. Amidst this, multidisciplinary treatment approaches are crucial in the management and control of the disease, accommodating the wide array of oncological diagnoses and patient needs. Over the years, the philosophy of cancer treatment has witnessed a fundamental shift, moving from a 'maximum tolerable' approach to a 'minimum effective' strategy. This evolution, firstly in breast cancer management and then in other oncological diagnosis, seeks to balance optimal therapeutic outcomes with the minimal negative impact on patients' quality of life, marking a significant advance in patient-centric care.
Crucial to these multidisciplinary strategies is not only the goal of clinical remission or control of the disease but also the holistic well-being of patients. Recognizing the essentiality of their emotional, psychological, and social health is paramount in formulating an effective treatment plan.
In the contemporary landscape of oncology, we find ourselves armed with a wider range of innovative technologies and treatment strategies than ever before. These advancements are not merely limited to surgical interventions but span the spectrum of systemic and locoregional treatments, empowering us with more tools to customize treatment strategies and design individualized care plans. Non operative management with surgical de-escalation or even surgical omission in several solid tumors and Chemotherapy-Sparing Regimen are only two examples of this physolophy, aiming at oncological disease chronicity, reduced side effect maintaining surgical safety.
In this Research Topic, our aim is to illuminate the latest developments in oncology from this perspective. We will focus on how evolving strategies in multidisciplinary treatment align with the broader objective of enhancing patients' quality of life. We intend to highlight the intricate relationships between different forms of systemic and locoregional treatments and their implications on patients' well-being, as well as the critical role of patient-reported outcomes (PROMs) in this context. Under this perspective, we strongly believe that no specific organ-based special issue should be held reducing the disease particularism, but a broaden oncological population cohort could enhance the scientific evidence in biologically different pathologies.
Accordingly, we invite submissions in the form of case reports, case series, technical notes, review articles, and original research papers that contribute to this conversation. We particularly encourage studies that delve into oncological outcomes and their integration with the broader framework of patient health and quality of life.
Thank you for contributing to this essential dialogue in oncology. Through our collective efforts, we can indeed bring about a positive difference in the lives of those affected by this formidable disease.
Please note: manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent clinical or patient cohort, or biological validation in vitro or in vivo, which are not based on public databases) are not suitable for publication in this journal.